Liquidia Corp Discloses Hatch-Waxman Lawsuit Over YUTREPIA

What Happened
On September 30, 2026, Liquidia Corporation (LQDA) filed an 8‑K (Item 8.01) and issued a press release reporting that United Therapeutics Corporation has filed litigation in the U.S. District Court for the District of Delaware under the Hatch‑Waxman Act. The dispute involves U.S. Patent No. 11,826,327 and Liquidia’s lead product, YUTREPIA® (treprostinil) inhalation powder. The press release is attached to the 8‑K as Exhibit 99.1.

Key Details

• Date filed: September 30, 2026 (8‑K and press release).
• Parties: Plaintiff — United Therapeutics Corporation; Defendant — Liquidia Corporation.
• Matter: Hatch‑Waxman litigation concerning U.S. Patent No. 11,826,327 and YUTREPIA (treprostinil) inhalation powder.
• Filing location: U.S. District Court for the District of Delaware.
• Exhibit: Press release included as Exhibit 99.1 to the 8‑K.

Why It Matters
The litigation directly involves Liquidia’s lead commercial product, YUTREPIA, and a patent dispute under the Hatch‑Waxman framework, which can affect market exclusivity and regulatory dynamics for pharmaceutical products. Investors should watch for further legal filings, company updates, and potential impacts on commercialization or competitive positioning; the 8‑K itself provides the company’s initial disclosure and the related press release.